A hospital-based multicentric study results on gestational trophoblastic disease management status in a developing country

European Journal of Gynaecological Oncology

Volumn 22, Issue 3, 2001, Pages 221-222

  Ozalp S S ^a   Yalcin O T ^a   Tanir, H M ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Gestational trophoblastic disease; Hospital based study; Management

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; METHOTREXATE; VINCRISTINE;

CANCER CHEMOTHERAPY; CONFERENCE PAPER; DEVELOPING COUNTRY; DISEASE CLASSIFICATION; DRUG PREFERENCE; DRUG USE; FEMALE; GESTATION PERIOD; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; TREATMENT INDICATION; TROPHOBLASTIC DISEASE; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEALTH SERVICES RESEARCH; HOSPITALS; HOSPITALS, MATERNITY; HOSPITALS, UNIVERSITY; HUMANS; PRACTICE GUIDELINES; PREGNANCY; TROPHOBLASTIC NEOPLASMS; TURKEY; UTERINE NEOPLASMS;

EID: 0034886357     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Gestational trophoblastic disease: Epidemiology
2. Treatment of metastatic trophoblastic diseases: Good and poor prognosis
3. Gestational trophoblastic disease
4. Gestational trophoblastic disease
5. Correlation between clinical staging and FIGO staging groups with gestational trophoblastic disease
6. Revised FIGO staging system for gestational trophoblastic tumours; recommendations regarding therapy
7. Assessing and staging of trophoblastic tumors
8. A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease
9. Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy
10. EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients
11. Persistent gestational trophoblastic disease: Results of MEA (methotrexate, etoposide, dactinomycin) as first-line chemotherapy in high-risk disease and EA (etoposide and dactinomycin) as second-line therapy for low-risk disease
12. Etoposide and cisplatin/etoposide, and actinomycin-D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/CO chemotherapy and patients presenting with metastatic placental site trophoblastic tumors